Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pat...
Website: criver.com



Growth: Bad revenue growth rate -7.9%, there is slowdown compared to average historical growth rates 12.7%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of +1.7%

Profitability: LTM EBITDA margin is positive, +22.5%. On average the margin is decreasing unsteadily. Gross margin is normal, +35.9%. In the last quarter the company beat the estimated EPS, +7.3%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.13 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 1.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 43.0% higher than minimum and 48.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.9x by EV / Sales multiple , the company can be 16.2% overvalued

Insiders: For the last 3 months insiders sold company shares on $5.8 mln (-0.045% of cap.)

Key Financials (Download financials)

Ticker: CRL
Share price, USD:  (+0.8%)235.27
year average price 214.62  


year start price 189.88 2023-05-08

min close price 164.52 2023-10-30

max close price 273.43 2024-03-21

current price 235.27 2024-05-07
Common stocks: 51 227 000

Dividend Yield:  0.0%
FCF Yield LTM: 1.0%
EV / LTM EBITDA: 15.5x
EV / EBITDA annualized: 14.1x
Last revenue growth (y/y):  -7.9%
Last growth of EBITDA (y/y):  -11.6%
Historical revenue growth:  12.7%
Historical growth of EBITDA:  11.9%
EV / Sales: 3.5x
Margin (EBITDA LTM / Revenue): 22.5%
Fundamental value created in LTM:
Market Cap ($m): 12 052
Net Debt ($m): 2 402
EV (Enterprise Value): 14 454
Price to Book: 4.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-06Zacks Investment Research

Charles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

2024-04-29Zacks Investment Research

ICLR vs. CRL: Which Stock Is the Better Value Option?

2024-04-24Zacks Investment Research

Charles River (CRL) to Report Q1 Earnings: Here's What to Expect

2024-04-16Zacks Investment Research

Here's Why You Should Retain Charles River (CRL) Stock Now

2024-04-12Zacks Investment Research

ICLR or CRL: Which Is the Better Value Stock Right Now?

2024-03-26Zacks Investment Research

Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine

2024-03-15Zacks Investment Research

Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?

2024-03-15Zacks Investment Research

Charles River (CRL) Extends Gene Therapy Offering With New Pact

2024-03-14Zacks Investment Research

Here's Why You Should Retain Charles River (CRL) Stock Now

2024-03-07InvestorPlace

The Top 3 Healthcare Stocks to Buy in March 2024
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2031 q4 2025 q3 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2031-12-01 2025-09-01 2023-12-30 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-09-24
symbol CRL CRL CRL CRL CRL CRL CRL CRL
reportedCurrency USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2023-02-22 2022-11-02 2024-02-14 2023-11-08 2023-08-09 2023-05-11 2023-02-22 2022-11-02
acceptedDate 2023-02-22 07:30:33 2022-11-02 07:30:51 2024-02-14 09:19:45 2023-11-08 09:06:25 2023-08-09 09:09:28 2023-05-11 09:08:55 2023-02-22 09:17:29 2022-11-02 16:13:44
calendarYear 2031.000 2025.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q4 Q3 Q2 Q1 Q4 Q3
revenue 1 100M 896M 1 013M 1 027M 1 060M 1 029M 1 100M 989M
costOfRevenue 701M 559M 649M 665M 661M 652M 701M 619M
grossProfit 399M 337M 364M 362M 399M 378M 399M 370M
grossProfitRatio 0.363 0.376 0.359 0.352 0.376 0.367 0.363 0.374
researchAndDevelopmentExpenses 0 0 0 0 0 0 0 0
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 200M 149M 197M 176M 200M 175M 200M 184M
otherExpenses 0 0 108M -6M -3M 35M 35M 36M
operatingExpenses 200M 149M 231M 210M 234M 210M 235M 219M
costAndExpenses 901M 707M 881M 875M 895M 861M 936M 838M
interestIncome 343 000 137 000 2M 1M 1M 806 000 343 000 122 000
interestExpense -35M -16M 34M 34M 35M 34M 35M 11M
depreciationAndAmortization -46M 49M 81M 79M 78M 75M 35M 58M
ebitda 164M 156M 323M 225M 241M 242M 315M 209M
ebitdaratio 0.149 0.174 0.318 0.220 0.228 0.236 0.287 0.211
operatingIncome 210M 107M 133M 152M 165M 168M 280M 151M
operatingIncomeRatio 0.191 0.119 0.131 0.148 0.156 0.163 0.254 0.153
totalOtherIncomeExpensesNet 35M 16M 108M -6M -3M -37M -35M -28M
incomeBeforeTax 245M 123M 209M 113M 129M 131M 245M 123M
incomeBeforeTaxRatio 0.223 0.138 0.206 0.110 0.121 0.127 0.223 0.124
incomeTaxExpense 56M 18M 20M 25M 29M 27M 56M 25M
netIncome 189M 105M 187M 87M 97M 103M 187M 96M
netIncomeRatio 0.172 0.117 0.185 0.085 0.092 0.100 0.170 0.098
eps 3.710 2.090 3.650 1.700 1.890 2.020 3.680 1.900
epsdiluted 3.680 2.040 3.620 1.690 1.890 2.010 3.650 1.880
weightedAverageShsOut 51M 50M 51M 51M 51M 51M 51M 51M
weightedAverageShsOutDil 51M 52M 52M 52M 51M 51M 51M 51M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2031 q4 2025 q4 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2031-12-05 2025-12-02 2023-12-30 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-09-24
symbol CRL CRL CRL CRL CRL CRL CRL CRL
reportedCurrency USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2023-02-22 2022-11-02 2024-02-14 2023-11-08 2023-08-09 2023-05-11 2023-02-22 2022-11-02
acceptedDate 2023-02-22 07:30:33 2022-11-02 07:30:51 2024-02-14 09:19:45 2023-11-08 09:06:25 2023-08-09 09:09:28 2023-05-11 09:08:55 2023-02-22 09:17:29 2022-11-02 16:13:44
calendarYear 2031.000 2025.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q4 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 5M 241M 277M 157M 200M 202M 234M 194M
shortTermInvestments 0 0 0 0 0 0 0 950 000
cashAndShortTermInvestments 5M 241M 277M 157M 200M 202M 234M 195M
netReceivables 0 643M 780M 799M 801M 788M 752M 778M
inventory 0 199M 380M 293M 285M 263M 256M 262M
otherCurrentAssets 0 191M 83M 93M 113M 92M 108M 181M
totalCurrentAssets 5M 1 274M 1 609M 1 444M 1 505M 1 448M 1 439M 1 415M
propertyPlantEquipmentNet 0 1 584M 2 034M 1 901M 1 927M 1 903M 1 857M 1 754M
goodwill 0 2 712M 3 095M 2 885M 2 917M 2 902M 2 850M 2 776M
intangibleAssets 0 80M 864M 886M 930M 958M 955M 968M
goodwillAndIntangibleAssets 0 2 792M 3 959M 3 771M 3 846M 3 860M 3 805M 3 744M
longTermInvestments 0 0 244M 302M 300M 294M 312M 290M
taxAssets 0 40M 40M 34M 39M 41M 41M 40M
otherNonCurrentAssets 0 1 334M 309M 155M 155M 154M 148M 140M
totalNonCurrentAssets 0 5 750M 6 586M 6 163M 6 268M 6 251M 6 164M 5 967M
otherAssets 0 0 0 0 0 0 0 1000.000
totalAssets 5M 7 024M 8 195M 7 607M 7 772M 7 699M 7 603M 7 383M
accountPayables 0 198M 169M 136M 140M 120M 206M 182M
shortTermDebt 0 3M 441M 422M 412M 0 0 47M
taxPayables 0 0 39M 45M 45M 38M 0 47M
deferredRevenue 0 220M 242M 250M 257M 262M 264M 328M
otherCurrentLiabilities 0 613M 203M 185M 199M 599M 621M 457M
totalCurrentLiabilities 0 1 033M 1 055M 994M 1 008M 981M 1 092M 1 014M
longTermDebt 0 2 917M 3 066M 2 905M 3 080M 3 162M 3 097M 3 306M
deferredRevenueNonCurrent 0 0 31M 29M 30M 29M 0 24M
deferredTaxLiabilitiesNonCurrent 0 240M 191M 185M 207M 212M 216M 196M
otherNonCurrentLiabilities 0 2 978M 192M 143M 148M 158M 175M 3 140M
totalNonCurrentLiabilities 0 3 399M 3 481M 3 262M 3 465M 3 561M 3 488M 3 697M
otherLiabilities 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 253M 419M 390M 402M 418M 390M 443M
totalLiabilities 0 4 432M 4 536M 4 256M 4 472M 4 543M 4 579M 4 711M
preferredStock 0 0 0 0 0 0 0 0
commonStock 0 505 000 513 000 514 000 513 000 512 000 509 000 510 000
retainedEarnings 0 981M 1 887M 1 720M 1 633M 1 536M 1 433M 1 280M
accumulatedOtherComprehensiveIncomeLoss 0 -165M -196M -268M -208M -239M -262M -396M
othertotalStockholdersEquity 0 1 718M 1 906M 1 853M 1 826M 1 811M 1 805M 1 742M
totalStockholdersEquity 0 2 535M 3 597M 3 306M 3 252M 3 109M 2 976M 2 627M
totalEquity 0 2 535M 3 659M 3 351M 3 300M 3 157M 2 976M 2 627M
totalLiabilitiesAndStockholdersEquity 5M 6 967M 8 195M 7 607M 7 772M 7 699M 7 603M 7 383M
minorityInterest 0 0 62M 45M 48M 48M 47M 0
totalLiabilitiesAndTotalEquity 5M 6 967M 8 195M 7 607M 7 772M 7 699M 7 603M 7 383M
totalInvestments 0 0 244M 302M 300M 294M 312M 291M
totalDebt 0 2 919M 3 066M 2 905M 3 080M 3 162M 3 097M 3 353M
netDebt -5M 2 678M 2 790M 2 747M 2 880M 2 960M 2 863M 3 159M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2031 q4 2025 q3 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2031-12-05 2025-09-05 2023-12-30 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-09-24
symbol CRL CRL CRL CRL CRL CRL CRL CRL
reportedCurrency USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2023-02-22 2022-11-02 2024-02-14 2023-11-08 2023-08-09 2023-05-11 2023-02-22 2022-11-02
acceptedDate 2023-02-22 07:30:33 2022-11-02 07:30:51 2024-02-14 09:19:45 2023-11-08 09:06:25 2023-08-09 09:09:28 2023-05-11 09:08:55 2023-02-22 09:17:29 2022-11-02 16:13:44
calendarYear 2031.000 2025.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 187M 103M 189M 88M 99M 104M 189M 98M
depreciationAndAmortization 0 0 81M 79M 78M 77M 78M 75M
deferredIncomeTax 0 0 -23M -12M -5M -12M -10M -12M
stockBasedCompensation 0 0 20M 23M 16M 13M 22M 22M
changeInWorkingCapital 0 0 38M 2M -51M -92M 57M -65M
accountsReceivables 0 0 26M -11M -14M -34M -151M 0
inventory 0 0 -18M -11M -24M -9M -2M -13M
accountsPayables 0 0 6M -2M 16M -41M -9M -25M
otherWorkingCapital 0 0 25M 26M -29M -8M 218M -27M
otherNonCashItems -187M -103M -84M 25M 11M 18M -101M 16M
netCashProvidedByOperatingActivities 187M 103M 221M 205M 148M 109M 235M 133M
investmentsInPropertyPlantAndEquipment 0 0 -78M -66M -67M -107M -89M -72M
acquisitionsNet 0 0 -145M 66M -75M -50M 163M 0
purchasesOfInvestments 0 0 -18M -14M -10M -13M -29M -21M
salesMaturitiesOfInvestments 0 0 3M 1M 990 000 2M 1M 3M
otherInvestingActivites 0 0 -250 000 -67M 75M -960 000 -2M -2M
netCashUsedForInvestingActivites 0 0 -238M -80M -77M -169M 44M -92M
debtRepayment 0 0 -321M -214M -160M -157M -408M -668M
commonStockIssued 0 0 6M 4M 0 12M 25M 0
commonStockRepurchased 0 0 -139 000 -38 000 -5M -19M -159 000 -24 000
dividendsPaid 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 444M 51M 93M 190M 134M 617M
netCashUsedProvidedByFinancingActivities 0 0 124M -163M -71M 25M -249M -52M
effectOfForexChangesOnCash 0 0 13M -6M -163 000 2M 15M -30 000
netChangeInCash 187M 103M 119M -43M -114 000 -32M 45M -11M
cashAtEndOfPeriod 187M 103M 284M 166M 209M 209M 241M 196M
cashAtBeginningOfPeriod 0 0 166M 209M 209M 241M 196M 207M
operatingCashFlow 187M 103M 221M 205M 148M 109M 235M 133M
capitalExpenditure 0 0 -78M -66M -67M -107M -89M -72M
freeCashFlow 187M 103M 143M 140M 81M 3M 146M 60M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-14 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-11 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-14 12:00 ET
Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance
2024-01-29 13:00 ET
Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test
2024-01-24 21:30 ET
Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
2024-01-23 21:30 ET
Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call
2024-01-16 13:00 ET
Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing
2024-01-08 13:00 ET
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
2023-12-18 13:00 ET
Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
2023-12-12 13:00 ET
Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening
2023-11-28 13:00 ET
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
2023-11-27 13:30 ET
Charles River Laboratories to Present at Evercore ISI Investor Conference
2023-11-16 13:00 ET
Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products
2023-11-13 14:04 ET
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
2023-11-13 14:00 ET
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
2023-11-09 13:00 ET
Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023
2023-11-08 12:00 ET
Charles River Laboratories Announces Third-Quarter 2023 Results
2023-10-19 12:00 ET
Charles River Launches Real-Time Research Model Ordering, Introducing an Important Digital Innovation to Research Models & Services Business
2023-10-16 12:30 ET
Charles River Laboratories Schedules Third-Quarter 2023 Earnings Release and Conference Call
2023-10-16 12:00 ET
Charles River Laboratories Provides Access to Relevant, Well-Characterized Pediatric PDX Collection for Oncology Research
2023-10-11 12:00 ET
Charles River Laboratories Achieves 90% Renewable Electricity Globally, Announces Progress on Environmental Goals
2023-09-26 12:00 ET
Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
2023-09-25 12:00 ET
Charles River Announces Opening of RightSourceSM Laboratory, Supporting Stevenage Biocluster
2023-09-20 12:30 ET
Charles River Laboratories to Host Virtual Investor Day
2023-09-14 12:00 ET
Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica
2023-09-11 12:00 ET
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
2023-09-06 12:00 ET
Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods
2023-08-24 12:00 ET
Charles River Laboratories Announces Plasmid Manufacturing Collaboration with Fondazione Telethon
2023-08-09 11:00 ET
Charles River Laboratories Announces Second-Quarter 2023 Results
2023-08-01 12:00 ET
Charles River Laboratories Expands Access to AAALAC-Accredited, Turnkey Research Space in Key Markets
2023-07-19 12:00 ET
Charles River Laboratories Schedules Second-Quarter 2023 Earnings Release and Conference Call
2023-06-13 08:30 ET
Charles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids
2023-06-12 12:00 ET
Charles River and Curigin Collaborate to Produce Oncolytic RNAi Gene Therapy
2023-06-08 20:30 ET
Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration
2023-06-05 12:00 ET
Charles River Laboratories to Present at William Blair and Jefferies Conferences
2023-05-31 15:35 ET
Wheeler Bio and Charles River Laboratories Announce Agreement to Build and Operate RightSource(SM) Laboratory
2023-05-31 12:00 ET
Charles River Laboratories and Wheeler Bio Announce Agreement to Build and Operate RightSourceSM Laboratory
2023-05-11 11:00 ET
Charles River Laboratories Announces First-Quarter 2023 Results
2023-05-01 12:00 ET
Charles River Laboratories Launches Next Generation Sequencing Services for Bacterial Identification and Fungal ID
2023-04-11 12:30 ET
Charles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call
2023-04-10 12:00 ET
Charles River Laboratories Showcases End-to-End Oncology Capabilities at AACR 2023
2023-03-13 12:00 ET
Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data
2023-03-13 12:00 ET
Charles River Laboratories to Present at Barclays Global Healthcare Conference
2023-03-09 13:00 ET
Charles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing
2023-02-22 12:00 ET
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
2023-02-16 13:00 ET
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
2023-02-15 21:31 ET
Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration
2023-02-13 13:00 ET
Charles River Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein
2023-02-09 13:30 ET
Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call
2023-01-30 12:00 ET
Charles River Laboratories Acquires SAMDI Tech
2023-01-26 13:00 ET
iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors
2023-01-18 13:00 ET
Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance
2023-01-16 13:00 ET
Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products
2023-01-12 13:00 ET
Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs
2023-01-09 21:15 ET
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
2022-12-06 13:00 ET
Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors
2022-12-01 13:00 ET
Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection
2022-11-28 13:00 ET
Charles River Laboratories Opens Contract Vivarium Space in Chicago, Enhancing Access to AAALAC-Accredited, Turnkey Research Program
2022-11-14 13:00 ET
Charles River Laboratories to Present at November Investor Conferences
2022-11-10 13:00 ET
Charles River Laboratories Demonstrates Excellence in Advanced Modalities at Neuroscience 2022
2022-11-07 13:00 ET
Charles River Announces Cell Therapy Manufacturing Capacity Expansion, Reinforcing Commitment to CDMO Clients
2022-11-02 11:00 ET
Charles River Laboratories Announces Third-Quarter 2022 Results
2022-10-19 12:00 ET
Charles River Launches HemaCare Donor App to Engage Diverse Donors and Source Cell Solutions for Critical Cell and Gene Therapy Research
2022-10-18 12:00 ET
Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership
2022-10-11 20:30 ET
Charles River Laboratories Schedules Third-Quarter 2022 Earnings Release and Conference Call
2022-10-10 12:00 ET
Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy Programs
2022-09-08 20:30 ET
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
2022-09-06 12:00 ET
Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration
2022-08-23 12:00 ET
Charles River Laboratories Expands Contract Vivarium Space on West Coast
2022-08-09 12:00 ET
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product
2022-08-03 11:00 ET
Charles River Laboratories Announces Second-Quarter 2022 Results
2022-07-11 12:30 ET
Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
2022-06-28 12:00 ET
Charles River Laboratories Announces Opening of U.K. Manufacturing Facility
2022-06-23 12:00 ET
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
2022-06-13 12:00 ET
Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A
2022-06-06 12:00 ET
Charles River Laboratories to Participate in Jefferies and William Blair Conferences
2022-05-04 11:00 ET
Charles River Laboratories Announces First-Quarter 2022 Results
2022-04-27 12:00 ET
Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets
2022-04-13 20:30 ET
Charles River Laboratories Schedules First-Quarter 2022 Earnings Release and Conference Call
2022-04-07 12:00 ET
Charles River Laboratories Publishes 2021 Corporate Citizenship Report
2022-04-06 12:00 ET
Charles River Laboratories Acquires Explora BioLabs
2022-03-28 12:00 ET
Charles River Laboratories to Appoint Flavia H. Pease as Chief Financial Officer
2022-02-16 12:00 ET
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results
2022-02-03 13:00 ET
Charles River Laboratories Announces Wind Contract with Repsol for European Operations
2022-01-27 13:00 ET
Charles River Expands Strategic Partnership With SAMDI Tech
2022-01-20 13:30 ET
Charles River Laboratories Schedules Fourth-Quarter 2021 Earnings Release and Conference Call
2022-01-19 14:00 ET
Charles River and Valo Health Announce Strategic Partnership to Provide Clients with Access to AI-Enabled Drug Discovery Solutions
2022-01-11 12:00 ET
Charles River Laboratories Announces Chief Financial Officer Retirement and Transition Plan
2022-01-06 13:00 ET
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
2021-11-16 13:00 ET
Charles River Laboratories to Participate in Upcoming Investor Conferences
2021-11-11 12:00 ET
Charles River Laboratories Promotes Birgit Girshick to Chief Operating Officer
2021-11-03 11:00 ET
Charles River Laboratories Announces Third-Quarter 2021 Results
2021-10-20 12:00 ET
Charles River Laboratories Plans to Increase CRADL Capacity in Cambridge
2021-10-18 13:07 ET
Charles River and ATEM Structural Discovery Announce Strategic Partnership to Provide Clients with Cryo-EM Capabilities
2021-10-13 20:30 ET
Charles River Laboratories Schedules Third-Quarter 2021 Earnings Release and Conference Call
2021-10-12 23:00 ET
Charles River Laboratories Announces Two Divestitures
2021-09-20 12:00 ET
Charles River Launches First Annual Healthcare Collaboration Report
2021-09-07 12:00 ET
Charles River Laboratories to Participate in September Investor Conferences
2021-08-04 11:00 ET
Charles River Laboratories Announces Second-Quarter 2021 Results
2021-07-13 12:30 ET
Charles River Laboratories Schedules Second-Quarter 2021 Earnings Release and Conference Call
2021-06-29 11:00 ET
Charles River Laboratories Completes Acquisition of Vigene Biosciences
2021-06-07 12:00 ET
Charles River Laboratories Announces Long-Term Solar Contract for North American Operations
2021-05-28 12:00 ET
Charles River Laboratories to Participate in June Investor Conferences
2021-05-26 20:30 ET
Charles River Laboratories to Host Virtual Investor Day
2021-05-17 11:00 ET
Charles River Laboratories to Acquire Vigene Biosciences to Enhance Gene Therapy Capabilities
2021-05-04 11:00 ET
Charles River Laboratories Announces First-Quarter 2021 Results
2021-04-13 12:30 ET
Charles River Laboratories Schedules First-Quarter 2021 Earnings Release and Conference Call
2021-04-06 12:00 ET
Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities
2021-03-31 11:00 ET
Charles River Laboratories Acquires Retrogenix
2021-03-29 20:15 ET
Charles River Laboratories Completes the Acquisition of Cognate BioServices
2021-03-23 20:30 ET
Charles River Laboratories Announces Closing of Senior Notes Offering
2021-03-09 13:00 ET
Charles River Laboratories Prices $1 Billion of Senior Notes
2021-03-08 14:15 ET
Charles River Laboratories Announces Planned Offering of $1 Billion of Senior Notes
2021-03-08 13:30 ET
Charles River Laboratories to Present at Barclays Global Healthcare Conference
2021-02-25 13:00 ET
Charles River Laboratories Announces Strategic Partnership with Kibur Medical to Advance Preclinical Oncology Studies
2021-02-17 12:08 ET
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance
2021-02-17 12:06 ET
Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development
2021-01-28 13:00 ET
Charles River Announces Strategic Partnership with Cypre, Expanding 3D In Vitro Services for Cancer Immunotherapy and Targeted Therapy Drug Screening
2021-01-20 13:30 ET
Charles River Laboratories Schedules Fourth-Quarter 2020 Earnings and 2021 Guidance Release and Conference Call
2021-01-14 13:00 ET
Charles River Partners with JADE Biomedical to Expand Biologics Capabilities
2021-01-11 13:00 ET
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
2021-01-04 12:00 ET
Charles River Laboratories Acquires Distributed Bio
2020-12-09 13:00 ET
Charles River Delivers Industry-First Deciphex Patholytix Digital Pathology Peer Review for GLP Studies
2020-11-12 13:00 ET
Charles River and PathoQuest Strengthen Strategic Partnership
2020-11-09 13:30 ET
Charles River Laboratories to Present at Upcoming Investor Conferences
2020-10-29 11:00 ET
Charles River Laboratories Announces Third-Quarter 2020 Results
2020-10-16 13:15 ET
Charles River Laboratories Adds George Llado to Board of Directors
2020-10-13 12:30 ET
Charles River Laboratories Schedules Third-Quarter 2020 Earnings Release and Conference Call
2020-09-08 12:30 ET
Charles River Laboratories to Present at September Investor Conferences
2020-08-05 11:00 ET
Charles River Laboratories Announces Second-Quarter 2020 Results
2020-07-14 12:30 ET
Charles River Laboratories Schedules Second-Quarter 2020 Earnings Release and Conference Call
2020-06-01 12:00 ET
Charles River Laboratories to Participate in Jefferies and William Blair Conferences
2020-05-07 11:00 ET
Charles River Laboratories Announces First-Quarter 2020 Results
2020-04-16 12:30 ET
Charles River Laboratories Schedules First-Quarter 2020 Earnings Release and Conference Call
2020-03-30 12:30 ET
Charles River Laboratories and Deciphex Form a Partnership to Enhance Drug Discovery & Development With Digital Pathology
2020-03-10 12:30 ET
Charles River Laboratories To Participate In Barclays Global Healthcare Conference
2020-03-04 13:00 ET
Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors
2020-02-11 12:00 ET
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance
2020-01-21 21:30 ET
Charles River Laboratories Schedules Fourth-Quarter 2019 Earnings and 2020 Guidance Release and Conference Call
2020-01-16 13:00 ET
Charles River Laboratories and Fios Genomics Form a Strategic Alliance to Provide Bioinformatics-driven Drug Discovery and Safety Assessment
2020-01-13 13:30 ET
Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates
2020-01-13 13:00 ET
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
2020-01-03 13:30 ET
Charles River Laboratories Completes the Acquisition of HemaCare Corporation
2019-12-16 19:33 ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HemaCare Corporation
2019-12-16 12:00 ET
Charles River Laboratories to Acquire HemaCare Corporation
2019-12-10 13:00 ET
Charles River Announces Strategic Partnership with Bit Bio, Increasing Portfolio of Translational Drug Discovery Technologies
2019-12-09 21:30 ET
Distributed Bio Launches Cosmic Antibody Library, Provides Charles River Clients Exclusive Access
2019-12-04 21:30 ET
Charles River Laboratories Updates Tumor Model Compendium
2019-11-06 12:00 ET
Charles River Laboratories Announces Third-Quarter 2019 Results

SEC forms

Show financial reports only

SEC form 8
2024-02-14 00:00 ET
Charles River Laboratories International published news for 2023 q4
SEC form 10
2024-02-14 00:00 ET
Charles River Laboratories International reported for 2023 q4
SEC form 8
2024-02-14 00:00 ET
Charles River Laboratories International published news for 2023 q4
SEC form 10
2023-11-08 09:06 ET
Charles River Laboratories International reported for 2023 q3
SEC form 8
2023-11-08 07:30 ET
Charles River Laboratories International published news for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Charles River Laboratories International reported for 2023 q3
SEC form 10
2023-08-09 09:09 ET
Charles River Laboratories International reported for 2023 q2
SEC form 6
2023-08-09 07:30 ET
Charles River Laboratories International published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Charles River Laboratories International reported for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Charles River Laboratories International published news for 2023 q2
SEC form 10
2023-05-11 09:08 ET
Charles River Laboratories International reported for 2023 q1
SEC form 6
2023-05-11 07:30 ET
Charles River Laboratories International published news for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Charles River Laboratories International published news for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Charles River Laboratories International reported for 2023 q1
SEC form 10
2023-02-22 09:17 ET
Charles River Laboratories International reported for 2022 q4
SEC form 6
2023-02-22 07:30 ET
Charles River Laboratories International published news for 2022 q4
SEC form 10
2023-02-22 00:00 ET
Charles River Laboratories International reported for 2022 q4
SEC form 8
2023-02-22 00:00 ET
Charles River Laboratories International published news for 2022 q4
SEC form 6
2022-12-06 17:30 ET
Charles River Laboratories International published news for 2022 q3
SEC form 6
2022-11-30 10:01 ET
Charles River Laboratories International published news for 2022 q3
SEC form 10
2022-11-02 16:13 ET
Charles River Laboratories International published news for 2022 q3
SEC form 6
2022-11-02 07:30 ET
Charles River Laboratories International published news for 2022 q3
SEC form 10
2022-11-02 00:00 ET
Charles River Laboratories International reported for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Charles River Laboratories International published news for 2022 q3
SEC form 10
2022-08-03 15:59 ET
Charles River Laboratories International published news for 2022 q2
SEC form 6
2022-08-03 07:30 ET
Charles River Laboratories International published news for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Charles River Laboratories International published news for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Charles River Laboratories International reported for 2022 q2
SEC form 6
2022-06-08 07:00 ET
Charles River Laboratories International published news for 2022 q1
SEC form 6
2022-05-12 17:07 ET
Charles River Laboratories International published news for 2022 q1
SEC form 10
2022-05-04 16:45 ET
Charles River Laboratories International published news for 2022 q1
SEC form 6
2022-05-04 07:30 ET
Charles River Laboratories International published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Charles River Laboratories International published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Charles River Laboratories International reported for 2022 q1
SEC form 6
2022-03-30 08:32 ET
Charles River Laboratories International published news for 2021 q4
SEC form 6
2022-03-28 08:55 ET
Charles River Laboratories International published news for 2021 q4
SEC form 10
2022-02-16 16:14 ET
Charles River Laboratories International published news for 2021 q4
SEC form 6
2022-02-16 07:30 ET
Charles River Laboratories International published news for 2021 q4
SEC form 8
2022-02-16 00:00 ET
Charles River Laboratories International published news for 2021 q4
SEC form 10
2022-02-16 00:00 ET
Charles River Laboratories International published news for 2021 q4
SEC form 6
2022-01-11 07:19 ET
Charles River Laboratories International published news for 2021 q4
SEC form 6
2021-12-27 16:42 ET
Charles River Laboratories International published news for 2021 q3
SEC form 6
2021-12-15 16:35 ET
Charles River Laboratories International published news for 2021 q3
SEC form 6
2021-11-12 08:09 ET
Charles River Laboratories International published news for 2021 q3
SEC form 6
2021-11-09 07:37 ET
Charles River Laboratories International published news for 2021 q3
SEC form 10
2021-11-03 16:01 ET
Charles River Laboratories International published news for 2021 q3
SEC form 6
2021-11-03 07:30 ET
Charles River Laboratories International published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Charles River Laboratories International published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
Charles River Laboratories International published news for 2021 q3
SEC form 10
2021-08-04 16:08 ET
Charles River Laboratories International published news for 2021 q2
SEC form 6
2021-08-04 07:30 ET
Charles River Laboratories International published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Charles River Laboratories International published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Charles River Laboratories International published news for 2021 q2
SEC form 6
2021-05-18 16:16 ET
Charles River Laboratories International published news for 2021 q1
SEC form 6
2021-05-10 17:19 ET
Charles River Laboratories International published news for 2021 q1
SEC form 10
2021-05-04 16:01 ET
Charles River Laboratories International published news for 2021 q1
SEC form 6
2021-05-04 07:30 ET
Charles River Laboratories International published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Charles River Laboratories International published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Charles River Laboratories International published news for 2021 q1
SEC form 6
2021-04-23 16:01 ET
Charles River Laboratories International published news for 2021 q1
SEC form 6
2021-03-29 17:18 ET
Charles River Laboratories International published news for 2020 q4
SEC form 6
2021-03-26 12:39 ET
Charles River Laboratories International published news for 2020 q4
SEC form 6
2021-03-23 16:42 ET
Charles River Laboratories International published news for 2020 q4
SEC form 6
2021-03-09 08:59 ET
Charles River Laboratories International published news for 2020 q4
SEC form 10
2021-02-17 16:28 ET
Charles River Laboratories International published news for 2020 q4
SEC form 6
2021-02-17 16:03 ET
Charles River Laboratories International published news for 2020 q4
SEC form 6
2021-02-17 07:30 ET
Charles River Laboratories International published news for 2020 q4
SEC form 10
2020-11-09 16:44 ET
Charles River Laboratories International published news for 2020 q3
SEC form 6
2020-10-29 07:38 ET
Charles River Laboratories International published news for 2020 q3
SEC form 6
2020-10-19 17:25 ET
Charles River Laboratories International published news for 2020 q3